Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg

Massimo Carlo Mauri, Martin Turner, Lucia S. Volonteri, Rossella Medori, Wolfgang Maier

Research output: Contribution to journalArticle

Abstract

Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9% of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P

Original languageEnglish
Pages (from-to)36-47
Number of pages12
JournalInternational Journal of Psychiatry in Clinical Practice
Volume13
Issue number1
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Risperidone
Safety
Injections
Odds Ratio
Social Adjustment
Polypharmacy
Microspheres
Prescriptions
Schizophrenia

Keywords

  • Antipsychotic
  • Injectable
  • Long-acting
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Dosing patterns in Europe : Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. / Mauri, Massimo Carlo; Turner, Martin; Volonteri, Lucia S.; Medori, Rossella; Maier, Wolfgang.

In: International Journal of Psychiatry in Clinical Practice, Vol. 13, No. 1, 03.2009, p. 36-47.

Research output: Contribution to journalArticle

@article{05e50d6e5f804f5095e74e749241c471,
title = "Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg",
abstract = "Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9{\%} of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P",
keywords = "Antipsychotic, Injectable, Long-acting, Risperidone, Schizophrenia",
author = "Mauri, {Massimo Carlo} and Martin Turner and Volonteri, {Lucia S.} and Rossella Medori and Wolfgang Maier",
year = "2009",
month = "3",
doi = "10.1080/13651500802411979",
language = "English",
volume = "13",
pages = "36--47",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Dosing patterns in Europe

T2 - Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg

AU - Mauri, Massimo Carlo

AU - Turner, Martin

AU - Volonteri, Lucia S.

AU - Medori, Rossella

AU - Maier, Wolfgang

PY - 2009/3

Y1 - 2009/3

N2 - Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9% of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P

AB - Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9% of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P

KW - Antipsychotic

KW - Injectable

KW - Long-acting

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=60749131650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749131650&partnerID=8YFLogxK

U2 - 10.1080/13651500802411979

DO - 10.1080/13651500802411979

M3 - Article

AN - SCOPUS:60749131650

VL - 13

SP - 36

EP - 47

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 1

ER -